Candid Therapeutics licensed a trispecific T-cell engager from WuXi Biologics today for autoimmune disease. Chairman & CEO Ken Song talks about T-cell engagers vs CAR-Ts for autoimmune
- blonca9
- Jan 6
- 1 min read
He describes two clinical programs that Candid currently has targeting BCMA and CD20. Plus, discovery programs with U.S. and China based antibody shops, as well as today's deal.











.png)




